OPRD1 — Delta-Opioid Receptor

OPRD1 — Delta-Opioid Receptor

Overview

OPRD1 (Delta-Opioid Receptor, DOR) encodes a G protein-coupled receptor (GPCR) that plays crucial roles in pain modulation, emotional processing, motor control, and neuroprotection. The delta-opioid receptor has emerged as a significant therapeutic target in neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Parkinson's Disease (PD), due to its neuroprotective properties against excitotoxicity, oxidative stress, and protein aggregation.

Gene Information

OPRD1 — Delta-Opioid Receptor

Overview

OPRD1 (Delta-Opioid Receptor, DOR) encodes a G protein-coupled receptor (GPCR) that plays crucial roles in pain modulation, emotional processing, motor control, and neuroprotection. The delta-opioid receptor has emerged as a significant therapeutic target in neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Parkinson's Disease (PD), due to its neuroprotective properties against excitotoxicity, oxidative stress, and protein aggregation.

Gene Information

<div class="infobox infix-gene">
<table>
<tr><th>Symbol</th><td>OPRD1</td></tr>
<tr><th>Full Name</th><td>Delta-Opioid Receptor (DOR)</td></tr>
<tr><th>Chromosomal Location</th><td>1p36.12</td></tr>
<tr><th>NCBI Gene ID</th><td>[4981](https://www.ncbi.nlm.nih.gov/gene/4981)</td></tr>
<tr><th>OMIM</th><td>[165070](https://www.omim.org/entry/165070)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000116381](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000116381)</td></tr>
<tr><th>UniProt</th><td>[P41143](https://www.uniprot.org/uniprot/P41143)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/anorexia" style="color:#ef9a9a">Anorexia</a>, <a href="/wiki/heroin-dependence" style="color:#ef9a9a">Heroin Dependence</a>, <a href="/wiki/opioid-addiction" style="color:#ef9a9a">Opioid Addiction</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>
</div>

Protein Structure and Function

Receptor Architecture

The delta-opioid receptor is a 372-amino acid GPCR characterized by:

• Seven transmembrane helices (TM1-TM7)
• Extracellular N-terminus with glycosylation sites
• Intracellular C-terminus involved in G protein coupling
• Conserved DRYLAIV motif in TM3 for G protein activation

Signal Transduction Mechanisms

OPRD1 couples to multiple G protein subtypes, activating diverse signaling cascades:

Gαi/o-dependent pathways:

• Inhibition of adenylyl cyclase → reduced cAMP
• Activation of inward rectifier K+ channels (GIRK)
• Modulation of voltage-gated calcium channels
• Activation of MAPK pathways (ERK1/2, JNK, p38)

• Receptor internalization and recycling
• Activation of PI3K/Akt survival signaling
• MAPK cascade modulation

Expression Pattern

OPRD1 exhibits region-specific expression throughout the central nervous system:

| Brain Region | Expression Level | Functional Significance |
|--------------|-----------------|------------------------|
| [Basal Ganglia](/brain-regions/basalganglia) | High | Motor control, reward processing |
| [Substantia Nigra](/brain-regions/substantia-nigra) | Moderate-High | Dopaminergic neuron survival |
| [Striatum](/brain-regions/striatum) | High | Movement regulation |
| [Hippocampus](/brain-regions/hippocampus) | Moderate-High | Memory, synaptic plasticity |
| [Cortex](/brain-regions/cortex) | Moderate | Cognitive processing |
| [Amygdala](/brain-regions/amygdala) | Moderate | Emotional processing |
| [Periaqueductal Gray](/brain-regions/periaqueductal-gray) | High | Pain modulation |

Role in Alzheimer's Disease

Amyloid-Beta Pathology

Delta-opioid receptor activation provides neuroprotection against amyloid-beta (Aβ) toxicity through multiple mechanisms [@chen2020]:

Neuroinflammation Modulation

OPRD1 plays a critical role in regulating neuroinflammatory responses in AD [@gadd2021]:

• Microglial activation: DOR agonists reduce pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6)
• Astrocyte function: Modulation of astrocytic reactivity and gliosis
• NF-κB pathway: Inhibition of nuclear factor kappa-B signaling
• COX-2 regulation: Reduced cyclooxygenase-2 expression

Cholinergic System Interactions

The cholinergic system, severely affected in AD, interacts with OPRD1 signaling:

• Cholinergic neurons express DOR and respond to delta-opioid ligands
• DOR agonism protects basal forebrain cholinergic neurons
• Potential for combination therapy with acetylcholinesterase inhibitors

Clinical Evidence

Postmortem studies of AD brain tissue reveal altered OPRD1 expression [@fabbri2020]:

• Reduced DOR density in the hippocampus and cortex
• Correlation between receptor loss and cognitive decline
• PET imaging with selective DOR ligands shows reduced binding in AD patients [@stoppelbein2022]

Role in Parkinson's Disease

Dopaminergic Neuron Protection

The substantia nigra pars compacta (SNc) expresses high levels of OPRD1, making it a therapeutic target for PD [@su2008]:

Alpha-Synuclein Toxicity

Delta-opioid receptor activation protects against α-synuclein-induced neurodegeneration [@hua2020]:

• Reduced α-synuclein aggregation
• Enhanced lysosomal degradation of α-synuclein
• Preservation of dopaminergic neuron viability

Clinical Observations

Postmortem studies demonstrate OPRD1 alterations in PD [@valentini2012]:

• Increased DOR binding in the striatum of PD patients
• Correlation with disease severity
• Potential compensatory upregulation

Lewy Body Dementia

OPRD1 is also implicated in Dementia with Lewy Bodies (DLB) [@catchlove2022]:

• Altered opioid receptor density in DLB brain
• Relationship to motor and non-motor symptoms
• PET imaging potential for differential diagnosis

Therapeutic Implications

Drug Development

Several delta-opioid receptor agonists have been investigated for neuroprotection:

| Compound | Status | Primary Target | Notes |
|----------|--------|----------------|-------|
| DPDPE | Research | DOR | First selective DOR agonist |
| DADLE | Research | DOR | Metabolically stable |
| SNC-80 | Research | DOR | Blood-brain barrier permeable |
| ARM390 | Research | DOR | Biased agonist |

Clinical Considerations

Potential benefits:

• Neuroprotection without addictive properties
• Oral bioavailability with appropriate compounds
• Combination potential with existing therapies

• Seizure risk at high doses
• Tolerance development
• Peripheral side effects

Combination Therapies

OPRD1-targeted approaches may combine with:

• [Levodopa](/therapeutics/levodopa) for enhanced dopaminergic function
• [Acetylcholinesterase Inhibitors](/therapeutics/cholinesterase-inhibitors) for AD
• [MAO-B Inhibitors](/therapeutics/maob-inhibitors) for PD
• [Antioxidants](/therapeutics/antioxidants) for oxidative stress

Excitotoxicity Protection

Delta-opioid receptor activation provides robust protection against excitotoxic cell death [@meng2019]:

Glutamate Toxicity Mitigation

• Reduced calcium influx through voltage-gated channels
• Enhanced potassium conductance
• Preserved mitochondrial function
• Reduced caspase activation

NMDA Receptor Modulation

• DOR activation indirectly modulates NMDA receptor activity
• Reduces glutamate-induced calcium overload
• Protects against excitotoxic cascades

Autophagy and Protein Clearance

OPRD1 signaling regulates autophagy, critical for clearing toxic protein aggregates [@liu2020]:

Mechanisms

Implications for Neurodegeneration

• Enhanced clearance of [tau protein](/proteins/tau-protein)
• Reduced [alpha-synuclein](/proteins/alpha-synuclein) aggregation
• Preservation of proteostasis

Genetic Associations

Polymorphisms

OPRD1 genetic variants have been associated with:

• Susceptibility to Alzheimer's disease
• Response to opioid analgesics
• Age of onset in Parkinson's disease
• Cognitive decline progression

Gene-Environment Interactions

• Interactions with environmental neurotoxins
• Modulation of pesticide exposure risk
• Response to pharmacotherapy

Research Frontiers

PET Imaging

Development of selective DOR PET ligands enables:

• In vivo visualization of receptor density
• Disease progression monitoring
• Therapeutic response assessment

Biased Agonism

Biased DOR agonists that favor β-arrestin signaling offer:

• Enhanced neuroprotection
• Reduced side effects
• Improved therapeutic windows

Gene Therapy

Viral vector delivery of OPRD1:

• Sustained receptor expression
• Targeted delivery to affected brain regions
• Potential disease modification

Brain Region Expression

The regional distribution of OPRD1 in the brain has been extensively characterized through postmortem studies, PET imaging, and animal models:

High Expression Regions:

• Striatum: Highest density in the dorsal striatum (caudate nucleus and putamen), involved in motor control and habit formation
• Nucleus Accumbens: Core and shell regions, critical for reward and motivation
• Periaqueductal Gray (PAG): Major site of endogenous opioid analgesia
• Thalamus: Moderate to high expression, particularly in the medial nuclei

• Hippocampus: CA1-CA3 regions and dentate gyrus; higher in the stratum radiatum and molecular layer
• Cortex: Layer-specific distribution, highest in layers II-III and V
• Amygdala: Particularly in the basolateral complex
• Substantia Nigra: Pars compacta dopaminergic neurons express DOR
• Ventral Tegmental Area (VTA): Dopaminergic neurons

• Cerebellum: Primarily in the granular layer
• Hypothalamus: Moderate expression in the arcuate nucleus
• Brainstem: Varying expression across nuclei

Aging and OPRD1

Age-Related Changes

The aging brain shows significant alterations in OPRD1 expression and function [@dietl2015]:

These changes may contribute to age-related cognitive decline and increased susceptibility to neurodegenerative diseases.

Neuroaging Mechanisms

Age-associated OPRD1 dysfunction involves:

• Oxidative damage: Accumulated ROS affects receptor structure and function
• Glycosylation changes: Altered post-translational processing
• Membrane lipid composition: Changes in receptor microdomain localization
• Epigenetic regulation: Altered promoter methylation and histone modifications

Neurophysiological Functions

Synaptic Plasticity

OPRD1 plays important roles in modulating synaptic plasticity [@chen2018]:

Long-Term Potentiation (LTP):

• DOR activation enhances LTP in the hippocampus
• Mechanisms involve NMDA receptor modulation

• Calcium handling improvements

• DOR agonism facilitates LTD induction
• GABAergic modulation involved
• AMPA receptor internalization

Presynaptic Modulation

DOR functions as a presynaptic receptor modulating neurotransmitter release:

• Glutamate release: Inhibition of vesicular glutamate release
• GABA release: Reduced inhibitory transmission
• Dopamine release: Modulation in striatum and VTA
• Acetylcholine release: Cholinergic neuron regulation

Ion Channel Regulation

OPRD1 signaling modulates multiple ion channels:

• Voltage-gated calcium channels: N-type and P/Q-type inhibition
• Potassium channels: GIRK channel activation
• Sodium channels: Modulation of sodium currents
• TRPV1: Cross-talk with capsaicin receptors

Preclinical Models

Animal Models

Several preclinical models have informed understanding of OPRD1 in neurodegeneration:

Cellular Models

• Primary neuronal cultures: Acute DOR agonist treatment
• Organotypic slice cultures: Long-term exposure studies
• iPSC-derived neurons: Patient-specific models
• Microglial cultures: Inflammation modulation studies

Clinical Translation

Biomarker Potential

OPRD1 PET ligands serve as biomarkers:

| Ligand | Target | Clinical Use |
|--------|--------|---------------|
| [^11C]DPDPE | DOR | Receptor occupancy |
| [^18F]DUPK | DOR | Imaging studies |
| [^11C]GR103545 | DOR | High affinity |

Therapeutic Windows

Key considerations for clinical development:

• Dose optimization: Neuroprotective vs. analgesic doses differ
• Temporal window: Early intervention may be more effective
• Combination approaches: Synergistic with other neuroprotectants

Molecular Signaling Cascades

Detailed Signal Transduction

The delta-opioid receptor activates multiple intracellular signaling pathways critical for neuroprotection [@tian2014]:

Primary Pathways:

• Gαi/o protein inhibits AC activity
• Reduced cAMP accumulation
• PKA activity modulation
• CREB phosphorylation alterations

• Ras activation via β-arrestin
• Raf-1 → MEK → ERK phosphorylation
• Nuclear translocation of ERK
• Gene expression regulation

• β-arrestin-dependent PI3K activation
• Akt phosphorylation at Ser473
• mTORC1 regulation
• Bad phosphorylation (anti-apoptotic)

• Gβγ subunits activate PLCβ
• IP₃ and DAG production
• Intracellular calcium release
• PKC activation

• cAMP-PKA interaction: Bidirectional modulation
• MAPK-PI3K crosstalk: Parallel survival signaling
• PKC cross-activation: Multiple kinase pathways
• Calcium-dependent proteases: Calpain regulation

Epigenetic Regulation

OPRD1 expression is epigenetically regulated:

• DNA methylation: Promoter methylation inversely correlates with expression
• Histone modifications: Acetylation at H3K9 enhances expression
• miRNA regulation: miR-339 and miR-212 target OPRD1 mRNA
• lncRNA interactions: Regulatory RNA-mediated control

Neuroinflammation Mechanisms

Microglial Modulation

OPRD1 activation significantly modulates microglial function [@xu2016]:

Anti-inflammatory Effects:

• Reduced IL-1β, TNF-α, and IL-6 release
• Increased IL-10 production
• Suppressed COX-2 and iNOS expression
• NF-κB pathway inhibition

• Reduced microglial ramification
• Decreased pro-inflammatory phenotypes
• Enhanced surveillance mode

• Modulated phagocytosis of debris
• Enhanced clearance of Aβ aggregates
• Improved neuronal debris removal

Astrocyte Interactions

Astrocytes express OPRD1 and respond to agonist stimulation:

• Reactive astrocytosis modulation: ReducedGFAP expression
• Glutamate uptake enhancement: Improved excitotoxicity protection
• Potassium buffering: Regulated K⁺ homeostasis
• Metabolic support: Enhanced lactate provision to neurons

Mitochondrial Dynamics

Mitochondrial Protection

OPRD1 agonists protect mitochondrial function through multiple mechanisms [@zhang2021]:

Mitochondrial Biogenesis:

• PGC-1α activation
• Increased mitochondrial DNA copy number
• Enhanced respiratory chain complex expression

• Reduced excessive fission (Drp1 inhibition)
• Enhanced fusion (Mfn1/2, OPA1)
• Balanced dynamics maintenance

• Reduced oxidative damage to mtDNA
• Enhanced repair mechanisms
• Improved mitochondrial protein synthesis

Bioenergetic Effects

• ATP production: Maintained cellular energy levels
• Membrane potential: Preserved ΔΨm
• Respiratory control: Maintained coupling efficiency
• Substrate utilization: Enhanced glucose metabolism

Cognitive Function

Learning and Memory

OPRD1 plays important roles in cognitive processes [@chen2018]:

Memory Formation:

• Enhanced consolidation through DOR activation
• Improved retrieval in contextual memory tasks
• Spatial memory preservation

• Prefrontal cortex DOR involvement
• Optimal arousal modulation
• Attention regulation

Prefrontal Cortex Function

OPRD1 modulates prefrontal cortical excitability [@hou2017]:

• Neuronal firing patterns: Regulated action potential generation
• Synaptic integration: Improved dendritic integration
• Network oscillations: Modulated gamma and theta rhythms
• Executive function: Enhanced cognitive flexibility

Therapeutic Development Pipeline

Preclinical Candidates

| Agent | Mechanism | Stage | Indication |
|-------|-----------|-------|------------|
| DPDPE | Full agonist | Preclinical | PD model |
| DADLE | Full agonist | Preclinical | AD model |
| TAN-67 | Agonist | Preclinical | Stroke |
| SB-205607 | Partial agonist | Preclinical | TBI |
| ODM-116 | Biased agonist | Lead optimization | PD |

Clinical Candidates

Currently, no DOR-targeted neuroprotective drugs are in clinical trials for neurodegenerative diseases. However:

• Repurposing potential: Existing DOR agonists for analgesia
• Formulation advantages: BBB-penetrant compounds available
• Safety profile: Established human safety data

Challenges and Solutions

Challenges:

Solutions:

Comparative Receptor Biology

Opioid Receptor Family

OPRD1 belongs to the opioid receptor family with distinct functions:

| Receptor | Gene | Primary Function | Neuroprotection |
|----------|------|-----------------|-----------------|
| μ (MOR) | OPRM1 | Analgesia | Moderate |
| δ (DOR) | OPRD1 | Neuroprotection | Strong |
| κ (KOR) | OPRK1 | Dysphoria | Variable |
| NOP | OPRL1 | Reward modulation | Mixed |

Evolutionary Conservation

• Phylogenetic history: Ancient receptor family
• Species conservation: High conservation across mammals
• Functional conservation: Similar signaling across species
• Isoform diversity: Multiple splice variants

Research Methodology

Detection Methods

Model Systems

• In vitro: Cell lines, primary neurons, organotypic cultures
• In vivo: Mouse, rat, non-human primate models
• Computational: Docking studies, molecular dynamics
• Clinical: PET studies, postmortem analysis

Future Directions

Unanswered Questions

Emerging Technologies

• Single-cell RNAseq: OPRD1 expression heterogeneity
• Optogenetics: Light-controlled DOR signaling
• Chemogenetics: DREADD-based approaches
• Gene editing: CRISPR-based OPRD1 modulation

Cross-Linking to Related Topics

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease) — DOR neuroprotection
• [Parkinson's Disease](/diseases/parkinsons-disease) — SNc protection
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies) — Receptor alterations
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — Neuroinflammation

Proteins and Pathways

• [Dopamine Receptors](/entities/dopamine-receptors) — Interaction with dopaminergic system
• [Alpha-Synuclein](/proteins/alpha-synuclein) — Aggregation and clearance
• [Tau Protein](/proteins/tau-protein) — Phosphorylation regulation
• [GPCR Signaling](/entities/g-protein-coupled-receptors) — Signal transduction
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy metabolism
• [Autophagy](/mechanisms/autophagy-pathways) — Protein clearance
• [Neuroinflammation](/mechanisms/neuroinflammation) — Glial activation

Therapeutics

• [Opioid-Based Neuroprotectants](/therapeutics/neuroprotective-agents) — Drug development
• [Parkinson's Disease Therapeutics](/therapeutics/parkinsons-treatments) — Combination approaches

Pathway & Interaction Diagram

Interactive diagram showing OPRD1's key relationships in the SciDEX knowledge graph (7 connections shown).

See Also

• [G Protein-Coupled Receptors](/entities/g-protein-coupled-receptors) — Receptor superfamily
• [Neuroprotection Mechanisms](/mechanisms/neuroprotection) — Cell survival pathways
• [Excitotoxicity](/mechanisms/excitotoxicity) — Glutamate toxicity
• [Oxidative Stress](/mechanisms/oxidative-stress) — ROS and neurodegeneration

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/4981)
• [UniProt](https://www.uniprot.org/uniprot/P41143)
• [Ensembl](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000116381)
• [Human Protein Atlas](https://www.proteinatlas.org/search/oprd1)
• [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/ObjectDetailsForward?name=OPRD1&objectClass=receptor)

References